Marker Therapeutics, Inc.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company pioneering a multi-antigen approach in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The company's unique cell therapy technology revolves around the selective expansion of non-engineered, tumor-specific T cells that recognize multiple tumor associated antigens (multiTAA) and kill tumor cells expressing those targets. This approach presents significant advantages over current engineered CAR-T and TCR-based therapies, including lower costs and easier manufacturing, reduced toxicity, and meaningful clinical benefit. Founded in 1992 and headquartered in the United States, Marker Therapeutics recently secured a $2.00M grant investment from the National Institutes of Health on 26 June 2023. The company's portfolio of T cell therapies presents a compelling therapeutic product profile, positioning Marker Therapeutics as a key player in the biotechnology industry.